NIH awards $20.6M for biodefense therapeutics development to Enanta Pharmaceuticals

Contract Overview

Contract Amount: $20,636,844 ($20.6M)

Contractor: Enanta Pharmaceuticals, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2011-09-27

End Date: 2015-08-31

Contract Duration: 1,434 days

Daily Burn Rate: $14.4K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 29

Pricing Type: COST NO FEE

Sector: R&D

Official Description: DEVELOPMENT OF THERAPEUTICS FOR BIODEFENSE

Place of Performance

Location: WATERTOWN, MIDDLESEX County, MASSACHUSETTS, 02472

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $20.6 million to ENANTA PHARMACEUTICALS, INC. for work described as: DEVELOPMENT OF THERAPEUTICS FOR BIODEFENSE Key points: 1. Contract focuses on critical biodefense research and development. 2. Enanta Pharmaceuticals, a biotechnology firm, is the sole awardee. 3. The contract duration spans over three years, indicating a significant project timeline. 4. The award type is a Definitive Contract, suggesting a well-defined scope. 5. The contract was awarded under full and open competition. 6. The primary objective is the development of novel therapeutics.

Value Assessment

Rating: fair

The contract value of $20.6 million for biodefense therapeutics development appears to be within a reasonable range for research and development in this specialized field. Benchmarking against similar contracts for novel drug development, especially for biodefense applications, is challenging due to the unique nature of the research and the specific pathogens targeted. However, the cost-no-fee (CNF) contract type suggests that the government is primarily reimbursing allowable costs, with the contractor bearing the risk of profit. This can sometimes lead to higher cost proposals as contractors may build in contingencies.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit a bid. The data shows 29 proposals were received, suggesting a robust level of interest and a competitive bidding process. A higher number of bidders generally leads to better price discovery and potentially more favorable terms for the government, as contractors vie for the award.

Taxpayer Impact: The full and open competition for this contract is beneficial for taxpayers as it likely resulted in a more competitive pricing structure and a wider pool of innovative solutions being considered for biodefense needs.

Public Impact

The primary beneficiaries are public health and national security, through the development of countermeasures against biothreats. The services delivered include research and development of novel therapeutic agents. The geographic impact is national, focusing on enhancing the nation's biodefense capabilities. Workforce implications include supporting specialized scientific and research personnel within the biotechnology sector.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The cost-no-fee (CNF) contract type, while shifting profit risk to the contractor, can sometimes lead to higher initial cost proposals due to built-in contingencies.
The long duration of the contract (over 3 years) necessitates ongoing monitoring to ensure milestones are met and costs remain controlled.
The specialized nature of biodefense research means that success is not guaranteed, and the return on investment is tied to the successful development of viable therapeutics.

Positive Signals

The award was made under full and open competition, indicating a competitive process that likely yielded a strong candidate.
The development of therapeutics for biodefense directly addresses critical national security and public health needs.
Enanta Pharmaceuticals' focus on infectious disease and viral research suggests relevant expertise for this contract.

Sector Analysis

This contract falls within the Biotechnology and Pharmaceutical Research and Development sector, a critical area for national security and public health. The market for biodefense therapeutics is specialized, driven by government funding and the need to counter emerging and existing biological threats. Comparable spending benchmarks are difficult to establish precisely due to the unique nature of biodefense research, but significant government investment is typical for developing countermeasures against potential pandemics or bioterrorism agents. This contract represents a specific investment in Enanta Pharmaceuticals' capabilities to address these threats.

Small Business Impact

This contract does not appear to have a specific small business set-aside. However, the prime contractor, Enanta Pharmaceuticals, is a publicly traded company, not a small business. There is no explicit information provided regarding subcontracting plans for small businesses. The impact on the small business ecosystem would depend on whether Enanta engages small businesses as subcontractors for specialized services or supplies.

Oversight & Accountability

Oversight for this contract would primarily reside with the National Institutes of Health (NIH), a component of the Department of Health and Human Services. Accountability measures are typically embedded within the contract's milestones, reporting requirements, and performance metrics. Transparency is facilitated through contract databases like FPDS-NG, which provide public access to award details. Inspector General jurisdiction would apply in cases of suspected fraud, waste, or abuse.

Related Government Programs

Biodefense Advanced Research Projects Agency (BARDA) programs
National Institute of Allergy and Infectious Diseases (NIAID) research grants
Department of Defense biodefense initiatives
Strategic National Stockpile development

Risk Flags

Potential for cost overruns in R&D projects
Scientific and technical feasibility risks
Long development timelines for therapeutics
Dependence on contractor's specialized expertise

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $20.6 million to ENANTA PHARMACEUTICALS, INC.. DEVELOPMENT OF THERAPEUTICS FOR BIODEFENSE

Who is the contractor on this award?

The obligated recipient is ENANTA PHARMACEUTICALS, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $20.6 million.

What is the period of performance?

Start: 2011-09-27. End: 2015-08-31.

What is Enanta Pharmaceuticals' track record in developing biodefense therapeutics prior to this contract?

Prior to this specific contract, Enanta Pharmaceuticals has a history focused on the development of small molecule drugs for viral infections and liver diseases. While their core expertise lies in virology and infectious diseases, which is relevant to biodefense, their public record does not prominently feature specific biodefense therapeutic development contracts of this scale. Their pipeline has included antivirals for Hepatitis C and respiratory syncytial virus (RSV). This contract with NIH represents a significant engagement in the biodefense arena, leveraging their existing virology expertise for a broader range of potential biothreat agents.

How does the value of this contract compare to other federal investments in biodefense therapeutics development?

The $20.6 million awarded to Enanta Pharmaceuticals is a substantial sum for a single contract focused on therapeutic development. However, it should be viewed within the broader context of federal biodefense spending, which can reach billions annually across various agencies like BARDA, NIH, and DoD. For instance, BARDA alone has awarded contracts in the hundreds of millions for vaccine and therapeutic development against specific threats like influenza or emerging infectious diseases. This contract represents a targeted investment in a specific company's capabilities for a defined set of biodefense objectives, rather than a broad-spectrum program.

What are the primary risks associated with this contract, and how are they being mitigated?

The primary risks associated with this contract are scientific and technical in nature, given the inherent uncertainty in drug development. There's a risk that the therapeutic targets may prove intractable, that candidate drugs may fail in preclinical or clinical testing, or that the development timeline extends significantly. Mitigation strategies are embedded in the contract structure. The Cost-No-Fee (CNF) nature shifts some financial risk to the contractor, incentivizing efficient cost management. The NIH will likely monitor progress through regular reporting, milestone reviews, and potentially site visits to assess technical progress and adherence to the research plan. The selection of Enanta Pharmaceuticals, presumably based on their scientific merit and prior research, also serves as a risk mitigation factor.

What is the expected program effectiveness and impact of this contract on national biodefense capabilities?

The expected program effectiveness hinges on Enanta Pharmaceuticals successfully developing and advancing novel therapeutic candidates against identified biothreat agents. If successful, this contract will contribute directly to enhancing national biodefense capabilities by providing new medical countermeasures that can be deployed during public health emergencies or acts of bioterrorism. The impact could range from preventing widespread illness and death to mitigating the economic and social disruption caused by such events. The ultimate effectiveness will be measured by the successful transition of developed therapeutics into viable medical countermeasures available for stockpiling or rapid deployment.

How has federal spending on biodefense therapeutics development evolved over the past decade?

Federal spending on biodefense therapeutics development has seen significant fluctuations and increases, particularly following major public health events and evolving threat assessments. Post-9/11, there was a substantial surge in funding for biodefense initiatives, including therapeutic development, aimed at protecting against bioterrorism agents like anthrax and smallpox. More recently, the COVID-19 pandemic has further underscored the importance of rapid therapeutic development, leading to increased investment in platforms and research for emerging infectious diseases. Agencies like BARDA and NIAID have consistently allocated substantial budgets, often in the hundreds of millions to billions annually, to support research, development, and procurement of medical countermeasures.

What is the significance of the 'Cost No Fee' (CNF) contract type in this context?

The 'Cost No Fee' (CNF) contract type is significant because it means the government agrees to pay the contractor's allowable costs incurred in performing the contract, but the contractor does not receive any profit. This type of contract is typically used when the level of risk is high, and the contractor's profit is uncertain, or when the government wants to minimize the contractor's incentive to inflate costs. In the context of R&D for biodefense therapeutics, where success is inherently uncertain, the CNF structure shifts the financial risk primarily to the contractor. While it can help control costs for the government, it may also lead contractors to propose higher base costs to cover their potential lack of profit and associated risks.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: NIHAI2010097

Offers Received: 29

Pricing Type: COST NO FEE (S)

Evaluated Preference: NONE

Contractor Details

Address: 500 ARSENAL ST, WATERTOWN, MA, 02472

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $39,847,676

Exercised Options: $20,636,844

Current Obligation: $20,636,844

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline